Kyverna Therapeutics, Inc.
NASDAQ:KYTXBiotechnology
-$0.12 today
- Market cap
- $283.23M
- Beta
- 1.96
- P/E (TTM)
- -3.1
- EPS (TTM)
- -$2.59
Volume 1.05M
Average 0.94M
Returns on capital
Kyverna Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-69.4%
avg -49.0%
ROIC
-65.0%
avg -62.5%
ROA
-54.9%
avg -50.2%
Analysis
ROA is currently the strongest return metric at -54.9% versus its period average of -50.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Warner Biddle | Chief Executive Officer & Director | USD 1.27M | 59 | — | — |
Naji Gehchan | Chief Medical & Development Officer | USD 975.07K | 44 | 18.00K | 0.04% |
Mayo Pujols | Chief Technology Officer | USD 591.36K | 56 | — | — |
Gregory Martini | Chief Financial Officer | USD 563.51K | 37 | — | — |
Christi L. Shaw | Executive Chairperson | USD 144.94K | 59 | — | — |
Dan Maziasz | Chief Business Officer | — | — | — | — |
Ritesh Srivastava | Chief Legal & Compliance Officer | — | — | — | — |
Cara Bauer | Chief Human Resources Officer | — | — | — | — |
Jessica Serra | Head of Investor Relations | — | — | — | — |
Tracy Rossin | Senior Vice President of Corporate Affairs | — | 49 | — | — |
Tom Van Blarcom | Senior Vice President & Head of Research | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Mar 13, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$2.00M
Sells
1
$292,775.60
Net Transaction Value
+$1.71M
Net buying
Most Active
SEIDENBERG BETH C
1 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Dec 18, 25Dec 18, 2025 | SEIDENBERG BETH C Indirect | Buy | $1M$999,997.50 |
| Dec 18, 25Dec 18, 2025 | Westlake BioPartners Opportunity Fund I, L.P. Indirect | Buy | $1M$999,997.50 |
| Dec 15, 25Dec 15, 2025 | Walker Karen Marie Direct | Sell | $292.8K$292,775.60 |
Summary
Insiders reported 2 buys worth $2.00M and 1 sells worth $292,775.60 over the last 12 months. That adds up to net buying of $1.71M. SEIDENBERG BETH C was the most active insider with 1 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Kyverna Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about KYTX's management, answered from reported figures.
Who manages KYTX?
Kyverna Therapeutics, Inc. (KYTX) lists 11 active executives. The top listed executive is Dan Maziasz, Chief Business Officer.
Are KYTX insiders buying or selling?
Recent insider activity shows net buying of $83.38M.
Continue the stock analysis
Jump to another research area for this company.